Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique and of probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Klabusay, Martin ^a   Kohutova, Viera ^a   Coupek, Petr ^b   Nenickova, Marie ^a   Tesarova, Eva ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CZECH GEOLOGICAL SURVEY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; CD40 LIGAND; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL;

EID: 34547554889     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/65237     Document Type: Article

References (26)

1. A W Thomson M T Lotze The Cytokine Handbook. 4th Academic Press London, UK 2003
2. S Singhal R Powles J Treleaven C Horton J Mehta Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study. Leukemia and Lymphoma 24 3-4 1997 301 307
3. K-Y Chiang L Lamb J Clark D Worthington-White I Rich P J Henslee-Downey Assessment of G-CSF stimulated BM hematopoietic stem cells in normal donors. Cytotherapy 4 1 2002 55 63
4. M Bewtra meenakshi.bewtra@uphs.upenn.edu G R Lichtenstein grl@nphs.upenn.edu Infliximab use in Crohn's disease. Expert Opinion on Biological Therapy 5 4 2005 589 599
5. L Etemad E B Yu elainey@amgen.com L A Wanke Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Managed Care Interface 18 4 2005 21 27
6. R Foa M Massaia S Cardona Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemkia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76 2 1990 393 400
7. J W Eklund T M Kuzel Interleukin-2 in the reatment of renal cell carcinoma and malignant melanoma. Cancer Treatment and Research 126 2005 263 287
8. W Hsu M S Lesniak mlesniak@surgery.bsd.uchicago.edu B Tyler H Brem Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. Journal of Neuro-Oncology 74 2 2005 135 140
9. G Meloni M Vignetti C Andrizzi S Capria R Foa F Mandelli Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leukemia and Lymphoma 21 5-6 1996 429 435
10. W Krenger J LM Ferrara Dysregulation of cytokines during graft-versus-host disease. Journal of Hematotherapy 5 1 1996 3 14
11. J K Garrett S C Jameson B Thomson Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology 113 1 2004 115 119
12. W J Jordan P A Brookes R M Szydlo J M Goldman R I Lechler M A Ritter IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood 103 2004 2 717 724
13. X Thomas C Hirschauer J Troncy Serum interleukin-6 levels in adult acute myelogenous leukemia: relationship with disease characteristics and outcome. Leukemia and Lymphoma 24 1997 3-4 291 300
14. A Wierzbowska H Urbańska-Ryś T Robak robaktad@psk2.am.Iodz. pl Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. British Journal of Haematology 105 2 1999 412 419
15. A Gause D Spickermann S Klein V Diehl M Pfreundschuh Elevation of circulating IL-6 in patients with acute non-lymphocytic leukemia. European Journal of Haematology 53 3 1994 178 180
16. R Lai S O'Brien T Maushouri Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95 5 2002 1071 1075
17. M Herold F Schmalzl H Zwierzina Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leukemia Research 16 6-7 1992 585 588
18. T Watanabe Y Kawano S Kanamaru Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Blood 93 1999 4 1157 1163
19. E F Kamper ekamper@cc.uoa.gr A D Papaphilis M K Angelopoulou Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia. Clinical Biochemistry 32 8 1999 639 645
20. Z Y Lu X G Zhang C Rodriguez Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 85 1995 9 2521 2527
21. T A Wynn IL-13 effector functions. Annual Review of Immunology 21 2003 425 456
22. E Fuhrmann-Benzakein M N Ma L Rubbia-Brandt Elevated levels of angiogenic cytokines in the plasma of cancer patients. International Journal of Cancer 85 1 2000 40 45
23. M A Sarmiento M F Palacios M P Scolnik Evolution of chronic lymphocytic leukemia. Predictive value of immunophenotype, sCD23 and morphology. Medicina 62 4 2002 305 312
24. J D Schwarzmeier M Shehata M Hilgarth The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. Leukemia and Lymphoma 43 3 2002 549 554
25. K Clodi Z Asgary S Zhao Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. British Journal of Haematology 103 1 1998 270 275
26. A Toren D Novick A Ackerstein R Or S Slavin A Nagler Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-α or donor lymphocytes following bone marrow transplantation. Bone Marrow Transplantation 18 4 1996 721 724